Pediatric Spinal Solitary Fibrous Tumor: A Systematic Review of a Rare Condition
Authors:
- Andrea TrezzaATAndrea Trezza
- Chiara B. RuiCRChiara B. Rui
- Stefano ChiaravalliSCStefano Chiaravalli
- Veronica BiassoniVBVeronica Biassoni
- Elisabetta SchiavelloESElisabetta Schiavello
- Sabina VennariniSVSabina Vennarini
- Ester OrlandiEOEster Orlandi
- Giorgio G. CarrabbaGCGiorgio G. Carrabba
- Maura MassiminoMaura Massimino
- Carlo G. GiussaniCarlo G. Giussani
Open Access
Abstract
Background: Spinal solitary fibrous tumors (SFTs) are a rare oncological entity, almost anecdotal in the pediatric population. They have a high relapse rate and represent an ongoing oncological challenge. Methods: In this article, we conducted a systematic review starting from a case report to highlight the current state of the art in managing these tumors. Results: Spinal solitary fibrous tumors (SFTs) are rare, slow-growing neoplasms that can be either intra- or extramedullary. Only a limited number of studies focus on primary pediatric spinal cord localization. Five pediatric cases of spinal SFT have been documented in the literature. On MRI, they typically present as highly vascularized, contrast-enhancing masses. Histologically, they are composed of spindle-shaped cells within a collagenous stroma featuring staghorn-shaped blood vessels. More aggressive subtypes, such as dedifferentiated SFTs, resemble high-grade sarcomas. The NAB2–STAT6 fusion is a key marker, driving EGFR signaling, collagen production, and fibrosis. Additional diagnostic markers include CD34, CD99, and Bcl-2. Surgical resection remains the primary treatment. In metastatic cases, chemotherapy—mainly with anthracyclines, dacarbazine, or temozolomide—is employed, although no standardized pediatric protocols exist. Anti-angiogenic agents, including tyrosine kinase inhibitors, have shown promise. Radiotherapy is used postoperatively for local disease control, but its impact on survival is still under investigation. Conclusions: Surgery remains the cornerstone of treatment, significantly impacting the natural history of the disease and symptom control. While clinical trials exploring radiotherapy and chemotherapy are ongoing in adults, no specific treatment protocol has been established for pediatric patients.Keywords
This publication has 77 references indexed in Scilit:
- Incidence of extrameningeal solitary fibrous tumorsCancer, 2020
- Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNetCancer, 2020
- The impact of histopathology and NAB2–STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytomaActa Neuropathologica, 2018
- Surgical management of spinal solitary fibrous tumor/hemangiopericytoma: a case series of 20 patientsEuropean Spine Journal, 2017
- Head and neck solitary fibrous tumors: a rare and challenging entityEuropean Archives of Oto-Rhino-Laryngology, 2015
- Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumorGenes, Chromosomes and Cancer, 2013
- Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumorCancer, 2011
- Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous TumourInvestigational New Drugs, 2009
- Infantile myofibromatosis of the central nervous systemChild's Nervous System, 2003
- Primary Neoplasms of the pleura. A report of five casesAmerican Journal of Industrial Medicine, 1992